- Home
- / Sage Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sage Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.5
2024-10-29
Market Capitalization
$517.7 M
2024-10-29
Revenue
$41.2 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.3M | 6.9M | 1.1B | 6.3M | 7.7M | 86.5M | 41.2M | ||||
| General and administrative expense | 9.7M | 25.3M | 39.4M | 62.9M | 201.4M | 345.8M | 197.0M | 183.5M | 227.7M | 274.5M | 216.4M |
| Operating expense total | 33.8M | 94.7M | 160.2M | 273.2M | 483.5M | 714.6M | 489.7M | 553.9M | 630.8M | 442.3M | |
| EBIT | (33.8M) | (94.6M) | (160.2M) | (273.2M) | (393.2M) | (708.1M) | 596.2M | (460.9M) | (547.0M) | (579.8M) | (432.4M) |
| EBIT margin, % | -435.6% | -10310.5% | 53.5% | -7116.7% | -670.7% | -1048.3% | |||||
| Interest expense | 8.0K | 178.0K | 1.2M | 3.1M | 20.3M | 27.8M | 9.6M | 2.9M | 14.2M | 38.7M | 31.7M |
| Pre tax profit | 606.1M | (457.9M) | (532.8M) | (541.5M) | (400.7M) | ||||||
| Net Income | (33.8M) | (94.5M) | (159.0M) | (270.1M) | (372.9M) | (680.2M) | 606.1M | (457.9M) | (532.8M) | (541.5M) | (400.7M) |
| EPS | (9.0) | (9.0) | (6.6) |